ONKAPSITI Trademark

Trademark Overview


On Tuesday, May 11, 2021, a trademark application was filed for ONKAPSITI with the United States Patent and Trademark Office. The USPTO has given the ONKAPSITI trademark a serial number of 90702295. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Tuesday, October 15, 2024. This trademark is owned by MyoKardia, Inc.. The ONKAPSITI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pha...
onkapsiti

General Information


Serial Number90702295
Word MarkONKAPSITI
Filing DateTuesday, May 11, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateTuesday, October 15, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 23, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; monoclonal antibodies for therapeutic use for treating viral infections, inflammatory diseases, cardiovascular diseases, auto-immune diseases, blood diseases, and cancers

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, August 10, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameMyoKardia, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBrisbane, CA 94005

Party NameMyoKardia, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBrisbane, CA 94005

Trademark Events


Event DateEvent Description
Friday, May 14, 2021NEW APPLICATION ENTERED
Tuesday, August 10, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, January 21, 2022NON-FINAL ACTION E-MAILED
Friday, January 21, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, January 21, 2022NON-FINAL ACTION WRITTEN
Tuesday, January 18, 2022ASSIGNED TO EXAMINER
Monday, July 18, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, July 18, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, July 18, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, July 20, 2022EXAMINERS AMENDMENT -WRITTEN
Wednesday, July 20, 2022EXAMINER'S AMENDMENT ENTERED
Wednesday, August 3, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 23, 2022PUBLISHED FOR OPPOSITION
Wednesday, July 20, 2022EXAMINERS AMENDMENT E-MAILED
Wednesday, July 20, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, July 20, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, August 23, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 18, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, March 29, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, March 29, 2023SOU EXTENSION 1 FILED
Wednesday, March 29, 2023SOU EXTENSION 1 GRANTED
Friday, March 31, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 3, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, October 3, 2023SOU EXTENSION 2 GRANTED
Tuesday, October 3, 2023SOU EXTENSION 2 FILED
Thursday, October 5, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 14, 2024SOU EXTENSION 3 FILED
Thursday, March 14, 2024SOU EXTENSION 3 GRANTED
Thursday, March 14, 2024SOU TEAS EXTENSION RECEIVED
Friday, March 15, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 15, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, October 15, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 15, 2024SOU EXTENSION 4 GRANTED
Tuesday, October 15, 2024SOU EXTENSION 4 FILED